compound 10 [PMID: 34704759]   Click here for help

GtoPdb Ligand ID: 11802

Compound class: Synthetic organic
Comment: Compound 10 is a long-acting prodrug of the TGFβR inhibitor BMS-986260 [1]. It contains a matriptase peptide substrate domain, that is cleaved by the protease selectively in the tumour microenvironment. Compound 10 is sufficiently soluble to allow parenteral administration.
We generated the chemical structure shown here from the SMILES provided in the disclosure [1].
This prodrug approach is proposed to limit exposure of non-tumour tissue to the active parent molecule.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 38
Hydrogen bond donors 15
Rotatable bonds 79
Topological polar surface area 576.33
Molecular weight 1789.85
XLogP 3.63
No. Lipinski's rules broken 3
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES NCCCC[C@@H](C(=O)Nc1ccc(cc1)COC(=O)NCOCCn1cnc(c1c1ccc2n(n1)c(C#N)cn2)c1ccc(c(c1)Cl)F)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@@H](C(=O)O)NC(=O)CC[C@@H](C(=O)O)NC(=O)CCCCCCCCCCCCCCCCC(=O)O)CC(C)C)CO
Isomeric SMILES Fc1ccc(cc1Cl)c1c(n(CCOCNC(=O)OCc2ccc(NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@H](NC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCCCC(=O)O)C(=O)O)C(=O)O)CO)CCCCN)cc2)cn1)c1ccc2n(n1)c(cn2)C#N
InChI InChI=1S/C84H121ClFN17O23/c1-56(2)45-67(99-75(110)53-124-44-42-122-39-36-90-74(109)52-123-43-41-121-38-35-89-70(105)32-29-65(82(116)117)98-72(107)33-30-66(83(118)119)97-71(106)20-15-13-11-9-7-5-3-4-6-8-10-12-14-16-21-76(111)112)81(115)100-68(50-104)79(113)92-49-73(108)96-64(19-17-18-34-87)80(114)95-59-25-22-57(23-26-59)51-126-84(120)94-55-125-40-37-102-54-93-77(58-24-27-62(86)61(85)46-58)78(102)63-28-31-69-91-48-60(47-88)103(69)101-63/h22-28,31,46,48,54,56,64-68,104H,3-21,29-30,32-45,49-53,55,87H2,1-2H3,(H,89,105)(H,90,109)(H,92,113)(H,94,120)(H,95,114)(H,96,108)(H,97,106)(H,98,107)(H,99,110)(H,100,115)(H,111,112)(H,116,117)(H,118,119)/t64-,65-,66-,67-,68-/m0/s1
InChI Key RRGOOOPOTXFKKZ-UNVBUFFDSA-N
Bioactivity Comments
Compound 10 potentiates the antitumour efficacy of anti-PD-1 checkpoint inhibitor monoclonal antibody treatment in the MC38 murine colon adenocarcinoma model (in which matriptase activity is upregulated). Antitumour efficacy of compound 10 was similar to that of the parent molecule in this model.